Featured Research

from universities, journals, and other organizations

First cancer immunotherapy for dogs developed

Date:
July 4, 2014
Source:
Veterinärmedizinische Universität Wien
Summary:
Nearly every second dog develops cancer from the age of ten years onward. A few therapies derived from human medicine are available for dogs. A very successful form of therapy by which antibodies inhibit tumor growth has not been available for animals so far. Scientists have developed, for the first time, antibodies to treat cancer in dogs.

The newly developed antibody brings hope for dogs.
Credit: Michael Bernkopf / Vetmeduni Vienna

Nearly every second dog develops cancer from the age of ten years onward. A few therapies derived from human medicine are available for dogs. A very successful form of therapy by which antibodies inhibit tumor growth has not been available for animals so far. Scientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna have developed, for the first time, antibodies to treat cancer in dogs. The scientists published their research data in the journal Molecular Cancer Therapeutics.

As in humans, cancers in dogs have complex causes. The interaction of the environment, food, and genetic disposition are the most well known factors. Today nearly all methods of human medicine are basically available for dogs with cancer, but this was not true of cancer immunotherapy so far.

So-called cancer immunotherapy -- which is the treatment of tumors by the use of antibodies -- has been established and used very successfully in human medicine for about 20 years. Since cancer cells bear very specific antigens on the surface, the corresponding antibodies bind to these molecules and thus inhibit tumor growth. The mechanism that becomes effective is a destructive signal sent by the antibody to the inside of the cancer cell and initiates its death. In a second mechanism, the immune system of the patient also destroys the "marked" tumor in a more efficient way.

The target is nearly identical in humans and dogs

Josef Singer and Judith Fazekas, both lead authors of the study, discovered that a receptor frequently found on human tumor cells (epidermal growth factor receptor or EGFR) is nearly 100 percent identical with the EGF receptor in dogs. In human medicine EGFR is frequently used as the target of cancer immunotherapy because many cancer cells bear this receptor on their surface. The so-called anti-EGFR antibody binds to cancer cells and thus triggers the destruction of the cells. "Due to the high similarity of the receptor in humans and dogs, this type of therapy should work well in dogs too," the scientists say. The binding site of the antibody to EGFR in man and dogs differs only in respect of four amino acids.

Antibody trimmed to "dog"

To ensure best possible binding of the antibody to cancer cells in dogs, the human antibody had to be trimmed to "dog" in the laboratory. In human medicine this process is known as the "humanization" of an antibody. The antibody originally produced in the mouse has to be adjusted to the species for which it is used. Singer and Fazekas replaced the corresponding elements in the "humanized" antibody with elements from the dog. In experiments on dog cancer cells in the laboratory it was found that the newly developed antibodies did, in fact, bind to canine cancer cells with greater specificity.

The head of the study, Professor Erika Jensen-Jarolim, explains as follows: "We expect dogs to tolerate these anti-cancer antibodies well. This will be investigated in clinical studies in the future and is expected to greatly improve the treatment as well as the diagnosis of cancer in dogs."

Improvement of diagnosis

The newly developed antibody provides an additional benefit for dogs. As in human medicine, antibodies can be coupled with signal molecules. When the antibody binds to a cancer cell in the organism, the coupled antibody -- in this case a radioactive isotope -- can be rendered visible and is thus able to show where tumors and even metastases are located. When the selected isotope also contributes to the decay of cancer cells, the approach is known as "theranostics" (therapy and diagnostics).

"The Veterinary Medical University, Vienna will be the first center in the world to offer the most modern immunological cancer diagnosis procedure for dogs. Of special interest to me as a doctor of human medicine is the fact that, by using this approach, we will be able to initiate improvements that will benefit humans as well," says Jensen-Jarolim.

The first anti-EGFR antibody (cetuximab) for cancer treatment in human medicine was developed by the company Merck. In humans it is primarily used for the treatment of bowel cancer. Cancer immunotherapy is mainly applied in combination with chemotherapy and radiotherapy. In veterinary medicine, immunotherapy will be employed for the treatment of mammary ridge cancer (milk line cancer) in dogs. It may also be used as part of a combination therapy.


Story Source:

The above story is based on materials provided by Veterinärmedizinische Universität Wien. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. Singer, J. Fazekas, W. Wang, M. Weichselbaumer, M. Matz, A. Mader, W. Steinfellner, S. Meitz, D. Mechtcheriakova, Y. Sobanov, M. Willmann, T. Stockner, E. Spillner, R. Kunert, E. Jensen-Jarolim. Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients. Molecular Cancer Therapeutics, 2014; 13 (7): 1777 DOI: 10.1158/1535-7163.MCT-13-0288

Cite This Page:

Veterinärmedizinische Universität Wien. "First cancer immunotherapy for dogs developed." ScienceDaily. ScienceDaily, 4 July 2014. <www.sciencedaily.com/releases/2014/07/140704134625.htm>.
Veterinärmedizinische Universität Wien. (2014, July 4). First cancer immunotherapy for dogs developed. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/07/140704134625.htm
Veterinärmedizinische Universität Wien. "First cancer immunotherapy for dogs developed." ScienceDaily. www.sciencedaily.com/releases/2014/07/140704134625.htm (accessed July 22, 2014).

Share This




More Plants & Animals News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

San Diego Zoo Welcomes New, Rare Rhino Calf

San Diego Zoo Welcomes New, Rare Rhino Calf

Reuters - US Online Video (July 21, 2014) — An endangered black rhino baby is the newest resident at the San Diego Zoo. Sasha Salama reports. Video provided by Reuters
Powered by NewsLook.com
Shark Sightings a Big Catch for Cape Tourism

Shark Sightings a Big Catch for Cape Tourism

AP (July 21, 2014) — A rise in shark sightings along the shores of Chatham, Massachusetts is driving a surge of eager vacationers to the beach town looking to catch a glimpse of a great white. (July 21) Video provided by AP
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
A Centuries' Old British Tradition Is Far from a Swan Song

A Centuries' Old British Tradition Is Far from a Swan Song

AFP (July 19, 2014) — As if it weren't enough that the Queen is the Sovereign of the UK and 15 other Commonwealth realms, she is also the owner of all Britain's unmarked swans. Duration: 02:18 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins